Please assess the completion status of the following clinical trial:

Trial Title: Safety of Remifentanil Infusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I-II status~* aged 18-60 years old~* presenting for ureterorenoscopy~Exclusion Criteria:~* history of hypertension~* asthma and chronic obstructive lung disease~* recent respiratory tract infections

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- ultiva,remifentanil,opioid,analgesic (Type: ACTIVE_COMPARATOR): Remifentanil:1.5ng/ml remifentanil infusion maintained at the end of the surgery
- control (Type: NO_INTERVENTION): Control:Remifentanil stopped at the end of the surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).